Visiox Pharmaceuticals Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines.
 
The strategic combination aims to position the newly combined entity as an emerging leader in the eye care sector with a strong portfolio of ophthalmic medicines.
 
Visiox’s products, including OMLONTI (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%, will grow Ocuvex’s market presence and accelerate the commercialization of these promising therapeutics. Going forward, the company will operate under the Ocuvex name, building on Visiox’s commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.
 
“The combination of Visiox and Ocuvex makes for a perfect match,” said Ryan S. Bleeks, CEO of Visiox. “We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”

More Pharma Mergers & Acquisitions